22.01.2024

The aim of the project is to supply preclinical data to answer some of the fundamental biological questions on how FLASH can be used clinically.

FLASH is a novel radiotherapy modality for cancer where the treatment is delivered at ultra-high dose rates about 1000 times faster than in conventional radiotherapy. It has received massive attention since pre-clinical FLASH studies have shown remarkable sparing of normal tissue, with unaltered tumour response, when compared to conventional dose rates (CONV). If the differential normal tissue sparing is confirmed broadly, FLASH may become a new leading cancer treatment modality with substantially reduced side effects.

This interesting PhD project will contribute to evidence within the biological effects of FLASH, and the project will be supervised by prof. Brita Singers Sørensen.

See the posting for application and more information: PhD project Enhancing the Biological Benefit in vivo to Improve Radiotherapy (au.dk)

Read more about the radiobiology research group